A 1994 survey indicated that only 13 health authorities in the UK were purchasing access to dual X-ray absorptiometry (DXA), the most accurate measure of osteoporosis risk. By 1998 the number of centres (including private facilities providing DXA) was 161. All these were sent a questionnaire concerning their activities. 124 (77%) responded, and the survey found that DXA machines operate, on average, for only 3.6 days a week. Funding of and access to diagnostic services for osteoporosis varies greatly. There is clear scope for greater ef®ciency in the use of existing DXA machines and more equitable access to diagnostic services is required for effective management of osteoporosis.
INTRODUCTION
As the National Institute for Clinical Excellence begins its task of evaluating new health technologies, there are high expectations that it will promote more equitable access to healthcare. Attention has largely focused on the inequity of postcode prescribing, but access to diagnostic services can be equally variable. Access to bone densitometry to assess osteoporosis risk is a case in point. In the past decade various non-invasive techniques have been developed that can accurately and reliably measure bone density, a key determinant of bone strength and risk of fracture. The investigation of choice is dual X-ray absorptiometry (DXA) 1 with a predictive value for fracture that is at least as good as that of blood pressure for stroke 2 .
Although osteoporosis has been acknowledged as a major public health problem and its prevention and treatment has been endorsed by the Department of Health 3 , access to bone density measurement has been slow to develop in the UK. In a national survey conducted by the National Osteoporosis Society in 1995 only thirteen health authorities were providing services that met Department of Health recommendations; the great majority provided no funding for bone densitometry. Since then an NHS executive letter, EL (96) 110, has instructed health authorities tò purchase bone density measurements by means of dual Xray absorptiometry for particular clinical indications'.
In the study reported here our aims were: (1) to investigate the level of densitometry provision in the UK NHS; (2) to assess the ef®ciency of current provision; and (3) to consider the implications for future development of services.
METHODS
Data were obtained by mailing a questionnaire to 161 centres across the UK that were recorded on a central database held by the National Osteoporosis Society as having access to bone densitometry. These included NHS teaching hospitals, district general hospitals and private units. A pilot questionnaire was developed and validated with several provider units before mailing. Data were requested on hours for which DXA machines were used for research and for NHS activity, contracts held with health authorities for 1997/1998 and for 1998/1999, scan costs, types of referral, waiting times and future provision. The questionnaire was mailed in July 1998 and non-responders were followed-up by telephone in September and by fax in November 1998.
RESULTS
124 (77%) units responded. Data were excluded from 54 units that were not providing a service for the NHS. Of the 70 remaining units, 44 (63%) were district general hospitals, 20 (29%) were teaching hospitals, and 6 (8%) were private units which provided some NHS scans.
Of the non-responders, 25 (67%) were district general hospitals and 12 (32%) were teaching hospitals. There was no signi®cant difference in geographical location between responders and non-responders or in time since services had been established.
Use of DXA machines in 1998 Figure 1 illustrates the average total number of operating hours DXA machines were in use per week distributed across centres. The mean number of NHS operating hours was 20 per week; with research activity the total mean operating hours was 25.7 per week. 52 units (74%) gave general practitioners (GPs) direct access to bone densitometry; 10 units (14%) provided direct access only for fundholding GPs; the remainder provided access through consultant referral. The average cost of scans per patient was £38 for non-fundholders (range £23±£125), £44 for fundholders (£25±£130) and £84 for private patients (£25±£130).
Referral criteria were classi®ed according to Department of Health recommendations for bone densitometry 4 ; details of referral rates were provided by 19 units (27%) and are shown in Table 1 .
DXA contracts 1997/98 and 1988/99
In 1997/98 25 units had a speci®c contract to provide bone densitometry for 30 health authorities. This rose in 1998/ 99 to 41 units holding contracts with 49 health authorities. The number of scans contracted for varied considerably by centre, as is shown in Figure 2 . The 16 centres with contracts for 51000 scans included GP fundholder referrals. Of the 22 centres with contracts for 4400 scans 5 included referrals from GP fundholders.
DISCUSSION
Data regarding use of DXA machines suggest that on average they are operating for 3.6 days per week. This represents an increase since the last survey, in 1994, which reported an average of 3 days per week 4 , but there is still considerable room for ef®ciency gains. The two centres operating in excess of 50 hours per week were both university hospitals with access to several machines. These results suggest that commissioners should focus on increasing access to existing machinesÐif they have spare capacity and where geographically feasibleÐrather than increasing the total number of machines available. The wide variation in average weekly operating hours re¯ects the variation in scans commissioned by purchasers.
J O U R N A L O F T H E R O Y A L S O C I E T Y O F M E D I C I N E
V o l u m e 9 3 J a n u a r y 2 0 0 0 The results indicate that a two-tier system did operate in some areas where GP fundholding status could secure direct access to bone densitometry. Fundholding, however, came to an end on 1 April 1999. The wide range of scan charges may re¯ect the type of service offered, which can vary from a computer printout to a full review and treatment recommendation by a consultant, or the difference in unit cost based on operating ef®ciency.
An analysis of referrals shows a considerable spread in the referrals received for each category. This may be because referring physicians had different priorities or because referral criteria varied between centres. However, the generalizability of these results is weakened by the poor response to this question: only 19 of 70 centres were able to provide any information. With the advent of clinical governance, audit of referrals needs to be routine practice so that commissioners are con®dent that scans are being targeted at those in greatest need.
The 60% increase in the number of health authorities contracting for DXA scans suggests that some, but far from all, commissioners have responded to central directives regarding bone densitometry. The full extent of commissioning is unclear given that 14% of centres provided no data on contracts for densitometry, either because they could not access such data or because they had no speci®c contract. Although densitometry may be included in block contracts most providers have had to negotiate speci®c agreements with their local health authority as to the level of scans that will be funded with the introduction of new technology. Future commissioners will require this information. With the end of fundholding, contracts will need to cover all GPs, whereas previously some GP fundholders had to purchase scans independently.
Conclusion
The ®ndings of this study are limited in that only 77% of known units responded to the survey and respondents were not always able to provide complete data. However, the overall pattern of provision is one of continued wide variation in services provided. The diversity of services offered across the UK re¯ects the haphazard way in which services have developed, with variable levels of funding for osteoporosis diagnostic services. As a result there is considerable inequity in access to such services. Bone densitometry is a valid and reliable diagnostic technique for osteoporosis and may be cost-effective in allowing expensive therapeutic agents to be targeted at those in greatest need. Access to adequate diagnostic services is integral to effective management of this condition.
